Pashna N Munshi
Overview
Explore the profile of Pashna N Munshi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Murthy H, Ahn K, Estrada-Merly N, Alkhateeb H, Bal S, Kharfan-Dabaja M, et al.
Transplant Cell Ther
. 2022 Jan;
28(4):187.e1-187.e10.
PMID: 35081472
T cell prolymphocytic leukemia (T-PLL) is a rare, aggressive malignancy with limited treatment options and poor long-term survival. Previous studies of allogeneic hematopoietic cell transplantation (alloHCT) for T-PLL are limited...
12.
Jacobson C, Chavez J, Sehgal A, William B, Munoz J, Salles G, et al.
Lancet Oncol
. 2021 Dec;
23(1):91-103.
PMID: 34895487
Background: Most patients with advanced-stage indolent non-Hodgkin lymphoma have multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory indolent non-Hodgkin lymphoma....
13.
Shadman M, Pasquini M, Ahn K, Chen Y, Turtle C, Hematti P, et al.
Blood
. 2021 Sep;
139(9):1330-1339.
PMID: 34570879
The relative efficacy of autologous hematopoietic cell transplant (auto-HCT) vs chimeric antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma (DLBCL) who achieve a partial remission (PR)...
14.
Orfali N, Zhang M, Allbee-Johnson M, Boelens J, Artz A, Brunstein C, et al.
Transplant Cell Ther
. 2021 Sep;
27(12):993.e1-993.e8.
PMID: 34507002
The in vivo depletion of recipient and donor T lymphocytes using antithymocyte globulin (ATG; Thymoglobulin) is widely adopted in allogeneic hematopoietic stem cell transplantation (HCT) to reduce the incidence of...
15.
Munshi P, Hamadani M, Kumar A, Dreger P, Friedberg J, Dreyling M, et al.
Transplant Cell Ther
. 2021 Aug;
27(9):720-728.
PMID: 34452722
Autologous (auto-) and allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities in contemporary treatment algorithms for mantle cell lymphoma (MCL). Chimeric antigen receptor (CAR) T cell therapy recently...
16.
Munshi P, Hamadani M, Kumar A, Dreger P, Friedberg J, Dreyling M, et al.
Bone Marrow Transplant
. 2021 Aug;
56(12):2911-2921.
PMID: 34413469
Autologous (auto-) or allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities for mantle cell lymphoma (MCL). Recently, chimeric antigen receptor (CAR) T-cell therapy received approval for MCL; however,...
17.
Schaar D, Pirsl F, Holtzman N, Steinberg S, Nashed J, Ruben C, et al.
Transplant Cell Ther
. 2021 Aug;
27(11):937.e1-937.e7.
PMID: 34380090
Subsequent cancer (SC) is a significant cause of morbidity and mortality in long-term survivors after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Chronic graft-versus-host disease (cGVHD) and treatment-related immunosuppression have been...
18.
Munshi P, Vesole D, Martin A, Davila O, Kumar S, Qazilbash M, et al.
Cancer
. 2021 Aug;
127(22):4233-4239.
PMID: 34374445
Background: Consolidative autologous hematopoietic stem cell transplantation (AHCT) is commonly used for patients with multiple myeloma (MM). We studied AHCT use and outcomes in patients with MM ≥75 years old....
19.
Skarbnik A, Donato M, Feinman R, Rowley S, Vesole D, Goy A, et al.
Transplant Cell Ther
. 2021 May;
27(5):391-403.
PMID: 33965177
Autologous hematopoietic stem cell transplantation (ASCT) is a standard-of-care treatment for many hematologic malignancies. Progression of disease after ASCT is the primary cause of treatment failure. In this Phase Ib...
20.
Scordo M, Wang T, Ahn K, Chen Y, Ahmed S, Awan F, et al.
JAMA Oncol
. 2021 May;
7(7):993-1003.
PMID: 33956047
Importance: Primary central nervous system lymphoma (PCNSL) requires induction and consolidation to achieve potential cure. High-dose therapy and autologous hematopoietic cell transplant (AHCT) is an accepted and effective consolidation strategy...